Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
On Feb 26, 2013, we reaffirmed our long-term recommendation on BlackRock, Inc. ( BLK - Analyst Report ) at Neutral. This reflects the company’s strong fourth-quarter results, which exceeded the Zacks Consensus Estimate by nearly 6%.
Why Neutral?
BlackRock’s fourth-quarter adjusted earnings came in at $3.96 per share, significantly surpassing the Zacks Consensus Estimate of $3.74. Better-than-expected results were primarily driven by augmented top line, partly offset by higher operating expenses. Moreover, increased asset under management (AUM) was a positive.
Following the fourth-quarter results, the Zacks Consensus Estimate for 2013 has gone up 3.3% to $15.47 per share. Likewise, the Zacks Consensus Estimate for 2014 has also advanced (up 5.3% to $17.63 per share). With the Zacks Consensus Estimates for both 2013 and 2014 increasing, the company now has a Zacks Rank #2 (Buy).
Moreover, BlackRock has been expanding primarily via acquisitions – domestic and overseas – leading to growth in AUM. The company has ample acquisition opportunities in the overseas markets like Europe, Middle East, Africa and the Asia Pacific.
Yet, elevated operating expenses remain a major concern for BlackRock. Though total operating expenses declined slightly on a year-over-year basis in 2012, increased regulatory compliance costs as well as higher marketing costs (related to the company’s new brand campaign) will keep the overall expenses high.
Other Investment Management Stocks Worth Considering
While we prefer BlackRock, other financial investment management stocks worth a look include AllianceBernstein Holding L.P. ( AB - Snapshot Report ) , Lazard Ltd. ( LAZ - Analyst Report ) and Virtus Investment Partners, Inc. ( VRTS - Snapshot Report ) . All these carry a Zacks Rank #1 (Strong Buy).
Read the full reports :
Analyst Report on BLK
Analyst Report on LAZ
Snapshot Report on AB
Snapshot Report on VRTS